Neurocrine Biosciences | NBIX - Stock


Neurocrine Biosciences reported $69M in Stock for its fiscal quarter ending in December of 2025.





Stock Change Date
AbbVie USD 4.95B 13M Dec/2025
Acadia Pharmaceuticals USD 34.67M 5.57M Dec/2025
Agios Pharmaceuticals USD 32.92M 886K Dec/2025
ALKERMES USD 196.62M 5.63M Dec/2025
Alnylam Pharmaceuticals USD 82.72M 7.34M Dec/2025
Amgen USD 6.22B 121M Dec/2025
Biogen USD 2.17B 41.3M Dec/2025
BioMarin Pharmaceutical USD 1.3B 83.29M Dec/2025
Cytokinetics USD 0 0 Dec/2023
Exelixis USD 27.4M 3.92M Sep/2025
Gilead Sciences USD 1.78B 40M Sep/2025
Halozyme Therapeutics USD 176.48M 9.32M Dec/2025
Incyte USD 101.06M 17.61M Dec/2025
Ionis Pharmaceuticals USD 10.47M 1.99M Sep/2025
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 69M 300K Dec/2025
Pfizer USD 11.47B 201M Sep/2025
Regeneron Pharmaceuticals USD 3.2B 53.6M Dec/2025
Repligen USD 170.46M 10.14M Dec/2025
Rigel Pharmaceuticals USD 13.3M 2.88M Sep/2025
Sarepta Therapeutics USD 914.74M 162.42M Dec/2025
Teva Pharmaceutical Industries USD 3.18B 144M Dec/2025
Ultragenyx Pharmaceutical USD 52.2M 5.7M Sep/2025
Vertex Pharmaceuticals USD 1.69B 60M Dec/2025